Related Experiment Video
Updated: Oct 19, 2025

Visualization of Neutrophil Extracellular Traps in Mesenteric Venules After Mesenteric Ischemia-Reperfusion Injury via Intravital Microscopy
Published on: September 27, 2024
Intraperitoneal vancomycin-induced immune thrombocytopenia
Ahmet Murt1, Tuba Ozkan Tekin2, Suleyman Sami Guzel3
1Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Nephrology, Istanbul University-Cerrahpasa, Istanbul, Turkey.
Abstract:
Vancomycin is one of the drugs used in the peritonitis treatment regimen of peritoneal dialysis patients. Intraperitoneal route is generally preferred to provide rapid elimination of infective agents. Systemic toxicities of certain drugs after intraperitoneal administration are not very clear. The same also applies to vancomycin, although it has a considerable amount of systemic absorption after intraperitoneal administration. We herein report a case of severe thrombocytopenia, which was seen during the treatment of a peritonitis attack in a peritoneal dialysis patient. Culture studies revealed methicillin resistant staphylococci as the causative agent and the patient received intraperitoneal vancomycin per sensitivity analysis. Thrombocyte levels dropped abruptly to 3,900/μl after 10 days of vancomycin treatment. Clinical criteria pointed out to vancomycin-related immune thrombocytopenia. Platelet levels did not recover with initial dexamethasone treatment and platelet transfusions. In the meantime, the clinical course was also complicated with intracranial bleeding. Intravenous immunoglobulin treatment was applied and dexamethasone was switched to high-dose methylprednisolone. This latter treatment generated a response and platelet levels gradually increased to normal levels. The patient could be discharged without any sequelae. There have been two previous intraperitoneal vancomycin-related immune thrombocytopenia cases in the literature. Previous cases were reviewed, and the present case was given in comparison with the previous cases.
Insights
Severe thrombocytopenia occurred in a peritoneal dialysis patient treated with intraperitoneal vancomycin for peritonitis. Prompted by this rare vancomycin-induced immune thrombocytopenia, treatment adjustments led to recovery.
Area of Science:
- Nephrology
- Pharmacology
- Hematology
Background:
- Peritoneal dialysis (PD) patients often develop peritonitis, requiring antibiotic treatment.
- Intraperitoneal vancomycin is a common treatment for PD-related peritonitis, but systemic toxicity is not fully understood.
- Vancomycin can be significantly absorbed systemically via the intraperitoneal route.
Observation:
- A PD patient presented with peritonitis caused by methicillin-resistant staphylococci.
- Intraperitoneal vancomycin was administered based on sensitivity testing.
- The patient developed severe thrombocytopenia (platelet count 3,900/μl) after 10 days of vancomycin treatment.
Findings:
- Clinical presentation and rapid drop in platelet count strongly suggested vancomycin-induced immune thrombocytopenia.
- Initial treatments with dexamethasone and platelet transfusions were ineffective.
- Intracranial bleeding complicated the clinical course.
- High-dose methylprednisolone treatment led to gradual recovery of platelet levels.
Implications:
- This case highlights a rare but serious adverse effect of intraperitoneal vancomycin in PD patients.
- Early recognition and aggressive management, including high-dose corticosteroids, are crucial for favorable outcomes.
- Further research into vancomycin's systemic absorption and toxicity profiles in PD is warranted.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

